Designing Clinical Trials for the Treatment of Membranous Nephropathy in the Anti-Phospholipase A2 Receptor 1 Era: Results of a NephCure Membranous Nephropathy Workshop
Primary membranous nephropathy is a common cause of adult-onset nephrotic syndrome, with an overall incidence of 12 cases per million per year. Primary membranous nephropathy is an autoimmune kidney disease; however, primary membranous nephropathy autoantigens remained elusive until 2009,...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-03-01
|
| Series: | Glomerular Diseases |
| Online Access: | https://karger.com/article/doi/10.1159/000544808 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850274782928437248 |
|---|---|
| author | Marco Prunotto Patrick H. Nachman Barbara S. Gillespie Laurence H. Beck Aliza M. Thompson Austin H. Hu Elizabeth A. Stafford Josh M. Tarnoff Brad H. Rovin |
| author_facet | Marco Prunotto Patrick H. Nachman Barbara S. Gillespie Laurence H. Beck Aliza M. Thompson Austin H. Hu Elizabeth A. Stafford Josh M. Tarnoff Brad H. Rovin |
| author_sort | Marco Prunotto |
| collection | DOAJ |
| description |
Primary membranous nephropathy is a common cause of adult-onset nephrotic syndrome, with an overall incidence of 12 cases per million per year. Primary membranous nephropathy is an autoimmune kidney disease; however, primary membranous nephropathy autoantigens remained elusive until 2009, when the M-type phospholipase A2 receptor 1 (PLA2R) was identified as a disease autoantigen. This was followed relatively rapidly by the identification of several other autoantigens. Autoantibodies against PLA2R are detectable in ≈75% of patients with primary membranous nephropathy. The discovery of circulating and deposited autoantibodies against PLA2R offers an opportunity in nephrology to personalize disease management. On January 14, 2023, NephCure Kidney International convened a scientific workshop in Arlington, Virginia, to discuss the state of the science on autoantibodies against PLA2R and considerations related to the incorporation of autoantibodies against PLA2R in drug development programs for membranous nephropathy. The present report captures the discussion that occurred at the Membranous Nephropathy Scientific Workshop. Primary membranous nephropathy is a common cause of adult-onset nephrotic syndrome, with an overall incidence of 12 cases per million per year. Primary membranous nephropathy is an autoimmune kidney disease; however, primary membranous nephropathy autoantigens remained elusive until 2009, when the M-type phospholipase A2 receptor 1 (PLA2R) was identified as a disease autoantigen. This was followed relatively rapidly by the identification of several other autoantigens. Autoantibodies against PLA2R are detectable in ≈75% of patients with primary membranous nephropathy. The discovery of circulating and deposited autoantibodies against PLA2R offers an opportunity in nephrology to personalize disease management. On January 14, 2023, NephCure Kidney International convened a scientific workshop in Arlington, Virginia, to discuss the state of the science on autoantibodies against PLA2R and considerations related to the incorporation of autoantibodies against PLA2R in drug development programs for membranous nephropathy. The present report captures the discussion that occurred at the Membranous Nephropathy Scientific Workshop. |
| format | Article |
| id | doaj-art-5dd3458bb2c74740b7cf3986a75e28d4 |
| institution | OA Journals |
| issn | 2673-3633 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Glomerular Diseases |
| spelling | doaj-art-5dd3458bb2c74740b7cf3986a75e28d42025-08-20T01:51:03ZengKarger PublishersGlomerular Diseases2673-36332025-03-015113314110.1159/000544808Designing Clinical Trials for the Treatment of Membranous Nephropathy in the Anti-Phospholipase A2 Receptor 1 Era: Results of a NephCure Membranous Nephropathy WorkshopMarco PrunottoPatrick H. NachmanBarbara S. GillespieLaurence H. BeckAliza M. ThompsonAustin H. HuElizabeth A. StaffordJosh M. TarnoffBrad H. Rovin Primary membranous nephropathy is a common cause of adult-onset nephrotic syndrome, with an overall incidence of 12 cases per million per year. Primary membranous nephropathy is an autoimmune kidney disease; however, primary membranous nephropathy autoantigens remained elusive until 2009, when the M-type phospholipase A2 receptor 1 (PLA2R) was identified as a disease autoantigen. This was followed relatively rapidly by the identification of several other autoantigens. Autoantibodies against PLA2R are detectable in ≈75% of patients with primary membranous nephropathy. The discovery of circulating and deposited autoantibodies against PLA2R offers an opportunity in nephrology to personalize disease management. On January 14, 2023, NephCure Kidney International convened a scientific workshop in Arlington, Virginia, to discuss the state of the science on autoantibodies against PLA2R and considerations related to the incorporation of autoantibodies against PLA2R in drug development programs for membranous nephropathy. The present report captures the discussion that occurred at the Membranous Nephropathy Scientific Workshop. Primary membranous nephropathy is a common cause of adult-onset nephrotic syndrome, with an overall incidence of 12 cases per million per year. Primary membranous nephropathy is an autoimmune kidney disease; however, primary membranous nephropathy autoantigens remained elusive until 2009, when the M-type phospholipase A2 receptor 1 (PLA2R) was identified as a disease autoantigen. This was followed relatively rapidly by the identification of several other autoantigens. Autoantibodies against PLA2R are detectable in ≈75% of patients with primary membranous nephropathy. The discovery of circulating and deposited autoantibodies against PLA2R offers an opportunity in nephrology to personalize disease management. On January 14, 2023, NephCure Kidney International convened a scientific workshop in Arlington, Virginia, to discuss the state of the science on autoantibodies against PLA2R and considerations related to the incorporation of autoantibodies against PLA2R in drug development programs for membranous nephropathy. The present report captures the discussion that occurred at the Membranous Nephropathy Scientific Workshop. https://karger.com/article/doi/10.1159/000544808 |
| spellingShingle | Marco Prunotto Patrick H. Nachman Barbara S. Gillespie Laurence H. Beck Aliza M. Thompson Austin H. Hu Elizabeth A. Stafford Josh M. Tarnoff Brad H. Rovin Designing Clinical Trials for the Treatment of Membranous Nephropathy in the Anti-Phospholipase A2 Receptor 1 Era: Results of a NephCure Membranous Nephropathy Workshop Glomerular Diseases |
| title | Designing Clinical Trials for the Treatment of Membranous Nephropathy in the Anti-Phospholipase A2 Receptor 1 Era: Results of a NephCure Membranous Nephropathy Workshop |
| title_full | Designing Clinical Trials for the Treatment of Membranous Nephropathy in the Anti-Phospholipase A2 Receptor 1 Era: Results of a NephCure Membranous Nephropathy Workshop |
| title_fullStr | Designing Clinical Trials for the Treatment of Membranous Nephropathy in the Anti-Phospholipase A2 Receptor 1 Era: Results of a NephCure Membranous Nephropathy Workshop |
| title_full_unstemmed | Designing Clinical Trials for the Treatment of Membranous Nephropathy in the Anti-Phospholipase A2 Receptor 1 Era: Results of a NephCure Membranous Nephropathy Workshop |
| title_short | Designing Clinical Trials for the Treatment of Membranous Nephropathy in the Anti-Phospholipase A2 Receptor 1 Era: Results of a NephCure Membranous Nephropathy Workshop |
| title_sort | designing clinical trials for the treatment of membranous nephropathy in the anti phospholipase a2 receptor 1 era results of a nephcure membranous nephropathy workshop |
| url | https://karger.com/article/doi/10.1159/000544808 |
| work_keys_str_mv | AT marcoprunotto designingclinicaltrialsforthetreatmentofmembranousnephropathyintheantiphospholipasea2receptor1eraresultsofanephcuremembranousnephropathyworkshop AT patrickhnachman designingclinicaltrialsforthetreatmentofmembranousnephropathyintheantiphospholipasea2receptor1eraresultsofanephcuremembranousnephropathyworkshop AT barbarasgillespie designingclinicaltrialsforthetreatmentofmembranousnephropathyintheantiphospholipasea2receptor1eraresultsofanephcuremembranousnephropathyworkshop AT laurencehbeck designingclinicaltrialsforthetreatmentofmembranousnephropathyintheantiphospholipasea2receptor1eraresultsofanephcuremembranousnephropathyworkshop AT alizamthompson designingclinicaltrialsforthetreatmentofmembranousnephropathyintheantiphospholipasea2receptor1eraresultsofanephcuremembranousnephropathyworkshop AT austinhhu designingclinicaltrialsforthetreatmentofmembranousnephropathyintheantiphospholipasea2receptor1eraresultsofanephcuremembranousnephropathyworkshop AT elizabethastafford designingclinicaltrialsforthetreatmentofmembranousnephropathyintheantiphospholipasea2receptor1eraresultsofanephcuremembranousnephropathyworkshop AT joshmtarnoff designingclinicaltrialsforthetreatmentofmembranousnephropathyintheantiphospholipasea2receptor1eraresultsofanephcuremembranousnephropathyworkshop AT bradhrovin designingclinicaltrialsforthetreatmentofmembranousnephropathyintheantiphospholipasea2receptor1eraresultsofanephcuremembranousnephropathyworkshop |